Jacob et al., 2024 - Google Patents
Antibody-drug conjugates targeting EGFR ligand Epiregulin inhibit colorectal tumor growth irrespective of RAS mutational statusJacob et al., 2024
View PDF- Document ID
- 13378749504411279657
- Author
- Jacob J
- Anami Y
- High P
- Liang Z
- Subramanian S
- Ghosh S
- AghaAmiri S
- Guernsey C
- Tran H
- Liu Q
- Rowe J
- Azhdarinia A
- Tsuchikama K
- Carmon K
- Publication year
- Publication venue
- bioRxiv
External Links
Snippet
Purpose The EGFR ligand, epiregulin (EREG), is highly expressed in colorectal cancers (CRCs) and a biomarker for predicting benefit in RAS wildtype patients receiving EGFR- targeted therapies. Here, we report the development and preclinical evaluation of EREG …
- 101800000155 Epiregulin 0 title abstract description 152
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10479997B2 (en) | Compositions and methods for diagnosis and treatment of prostate cancer | |
| Kearns et al. | Enhanced targeting of the EGFR network with MM-151, an oligoclonal anti-EGFR antibody therapeutic | |
| US20250043009A1 (en) | Guided combinational therapeutic antibody | |
| JP2020504147A (en) | PSGL-1 antagonists and uses thereof | |
| US20230383005A1 (en) | Anti-cd46 antibodies and methods of use | |
| WO2018113136A1 (en) | Tpbg antibody and preparation method therefor and conjugate and application thereof | |
| Jacob et al. | Antibody-drug conjugates targeting EGFR ligand Epiregulin inhibit colorectal tumor growth irrespective of RAS mutational status | |
| US20230302050A1 (en) | Single Domain Antibodies and Their Use in Cancer Therapies | |
| KR20220155588A (en) | GPC3 CAR-T cell compositions and methods of making and using the same | |
| Jacob et al. | Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal Cancer | |
| US12122845B2 (en) | Anti-HER2/anti-4-1BB bispecific antibodies and uses thereof | |
| US20240336689A1 (en) | Treatment of cancers with an antibody that binds lgr5 and egfr | |
| Zhou et al. | A Dual-Payload Antibody–Drug Conjugate Targeting CD276/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer | |
| CN114616245B (en) | anti-CD 38 antibody and application thereof | |
| EP4384200A1 (en) | Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases | |
| US12139536B2 (en) | Guided combinational therapeutic antibody | |
| WO2020172218A1 (en) | Antibodies and enonomers | |
| US12006502B2 (en) | Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell | |
| WO2018217459A2 (en) | Conditional internalization of pegylated agents by pretargeting bi-specific peg-binding antibodies for diagnosis and therapy | |
| Zarrabi et al. | Unmet Potential of Antibody-Drug Conjugates: An Evaluation of the Past, Present, and Future of Antibody-Drug Conjugate Development in Advanced Urothelial Carcinoma | |
| WO2025019340A2 (en) | Cd276 antibody and methods of use thereof | |
| Li et al. | Fully human anti-B7-H3 recombinant antibodies inhibited tumor growth by increasing T cell infiltration | |
| TW202432186A (en) | Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof | |
| Wang et al. | Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors | |
| Li et al. | OBI-992, a Novel TROP2-Targeted Antibody–Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models |